Innate Pharma (IPHA) Income from Continuing Operations (2019 - 2025)
Innate Pharma posted quarterly Income from Continuing Operations of 57244167.92 for Q4 2025, down 8.28% year-on-year from 62415096.26 in Q4 2024, and down 136.93% on a QoQ basis from 24160547.58 in Q2 2025.
Innate Pharma (IPHA) has 7 years of Income from Continuing Operations data on file, last reported at 57244167.92 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations fell 8.28% year-over-year to 57244167.92; the trailing twelve-month figure through Dec 2025 stood at 160937242.48 (down 84.86% YoY), and the FY2025 full-year result was 57244167.92, down 8.28% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 57244167.92, down from 24160547.58 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 7525492.21 in Q2 2021 and bottomed at 57244167.92 in Q4 2025.
- The 5-year median for Income from Continuing Operations is 24160547.58 (2025), against an average of 23669195.89.
- The widest annual swing landed in 2021, when Income from Continuing Operations jumped 166.11%; it then tumbled 13670.83% in 2023.
- A 5-year view of Income from Continuing Operations shows it stood at 52025510.92 in 2021, then surged by 99.89% to 59145.78 in 2022, then sank by 13670.83% to 8144865.11 in 2023, then slumped by 549.05% to 52864483.04 in 2024, then slipped by 8.28% to 57244167.92 in 2025.
- The last three Income from Continuing Operations figures came in at 57244167.92 (Q4 2025), 24160547.58 (Q2 2025), and 52864483.04 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | -8.50 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 727.20 Mn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | -3.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Innate Pharma | 199.64 Mn | 199.64 Mn | - | -57.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -57.24 Mn |
| Jun 30, 2025 | -24.16 Mn |
| Dec 31, 2024 | -52.86 Mn |
| Jun 30, 2024 | -26.67 Mn |
| Dec 31, 2023 | -8.14 Mn |
| Jun 30, 2023 | 618,509.05 |
| Dec 31, 2022 | -59,145.78 |
| Dec 31, 2021 | -52.03 Mn |
| Jun 30, 2021 | 7.53 Mn |
| Dec 31, 2020 | -988,408.29 |
| Jun 30, 2020 | -11.38 Mn |
| Dec 31, 2019 | -22.98 Mn |